MK 1775 - AZD 1775 | Adavosertib

Based on 205 reference(s) in Google Scholar 10 10 205

Axon 1494

CAS [955365-80-7]

MF C27H32N8O2
MW 500.60

Purity: 99%
Soluble in 0.1N HCl(aq) and DMSO

MK 1775

Description

A potent and selective Wee1 kinase inhibitor in vitro and in vivo. MK 1775 abolishes cyclin-dependent kinase 1 (CDC2) activity by phosphorylation of the Tyr15 residue. It abrogates a DNA damage checkpoint (G2-phase), leading to apoptosis in combination with several DNA-damaging agents selectively in p53-deficient tumor cell lines. It is under clinical trial for advanced solid tumors.

H. Hirai et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol. Cancer. Ther. 2009, 8(11), 2992-3000.?

S. Schellens et al. A Phase I and pharmacological study of MK-1775, a Wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J. Clin. Oncol. 2009, 27.?

H. Hirai et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol. Ther. 2010, 9(7), 523-525.?

CC Porter et al. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia.?Leukemia 2012, 26, 1266-1276.??

List of publications using MK 1775 (Axon 1494) purchased from Axon Medchem

Certificate of Analysis
Material Safety Data Sheet

Cell Cycle Regulation Cell Signaling & Oncology Stem Cell DNA-damage Response Wee1 EC 2.7.10.2

Wee1 kinase inhibitor

Chemical name

2-Allyl-1-[6-(1-hydroxy-1-methyl-ethyl)-pyridin-2-yl]-6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-1,2-dihydro-pyrazolo[3,4-d]pyrimidin-3-one

Parent CAS No.

[955365-80-7]

產(chǎn)品資料